Emphysema – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030
A disorder affecting the alveoli (tiny air sacs) of the lungs. In emphysema, the alveoli become abnormally inflated, damaging their walls and making it harder to breathe. Emphysema is a type of COPD (chronic obstructive pulmonary disease).
Etiology-
The cause
of emphysema is usually long-term exposure to irritants that damage your lungs
and the airways. In the United States, cigarette smoke is the main cause. Pipe,
cigar, and other types of tobacco smoke can also cause emphysema, especially if
someone inhales them.
Rarely, a genetic
condition called alpha-1 antitrypsin deficiency can play a role in causing
emphysema.
Epidemiology-
The
prevalence of emphysema in the United States is approximately 14 million, which
includes 14% white male smokers and 3% white male nonsmokers. The prevalence is
slightly less for white female smokers and African Americans. In 2016, the
Global Burden of Disease Study reported a prevalence of 251 million cases of COPD
globally.
The competitive landscape of Emphysema
includes country-specific approved as well as pipeline therapies. Any asset/product-specific
designation or review and Accelerated Approval are being tracked and
supplemented with analyst commentary.
KOLs insights of Emphysema
across 8 MM market from the centre of Excellence/ Public/ Private hospitals
participated in the study. Insights around current treatment landscape,
epidemiology, clinical characteristics, future treatment paradigm, and Unmet
needs.
Emphysema
Market Forecast:
Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data
Inputs with sourcing, Market Event, and Product Event, Country specific
Forecast Model, Market uptake and patient share uptake, Attribute Analysis,
Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
S. No Asset Company Stage
1 PROCHYMAL™ Mesoblast,
Inc. Phase 2
2 Inhaled Treprostinil United
Therapeutics Phase 2/3
3 Alpha-1 MP Grifols
Therapeutics LLC Phase 3
4 Alvelestat Mereo
BioPharma Phase 2
Comments
Post a Comment